Bini C, Marcellusi A, Mennini FS, Ripoli S, Fioravanti L, Paly VF, Molinari A, Morelli P, Krotneva S, Li S. Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy. Grhta [Internet]. 2024 Dec. 10 [cited 2025 Jan. 22];11(1):248-57. Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/3167